In TME, as well as in a physiological context, the major producers of ECM components are stromal cells (Table 2), which, in this scenario, are recruited and orchestrated by tumor cells through their production of pro-fibrotic growth and inflammatory factors, such as TGF-β, fibroblast growth factor (FGF)-2, platelet-derived growth factor (PDGF) and epidermal growth factor (EGF) [145]. The gene discussed is FGF2; the disease is neoplasm.